Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2023-03-30 Declaration of Voting R…
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, board appointments, and other resolutions passed during the meeting held on March 30, 2023. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2023-03-30 Korean
사업보고서 (2022.12)
Annual Report Classification · 1% confidence The document is a comprehensive 'Business Report' (사업보고서) for the 12th fiscal year (2022.01.01-2022.12.31) of Aptamer Sciences Inc. It contains detailed financial statements, management discussion and analysis, governance information, and operational details. This is the standard Korean regulatory filing equivalent to a 10-K annual report. FY 2022
2023-03-22 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Aptamer Science. It contains the meeting agenda, details on voting procedures, and management's reference materials (including financial statements, audit reports, and business overviews) required for shareholders to make informed decisions. This type of document is standard for Proxy Solicitation and Information Statements, as it provides the necessary information for shareholders to vote on board proposals and financial approvals.
2023-03-15 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with many other companies, citing audit report timelines and operational preparation. Since this is a regulatory disclosure regarding the scheduling of a shareholder meeting rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2023-03-13 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from Aptamer Sciences announcing the submission of its audit report (감사보고서 제출). It provides key financial data, audit opinions, and financial ratios (capital impairment, operating losses) as required by regulatory disclosure standards. Since it is a formal announcement of the audit report submission rather than the full audit report document itself, and it follows the standard format for such regulatory disclosures in Korea, it is classified as a Report Publication Announcement (RPA). FY 2022
2023-03-13 Korean
전환가액의조정(제1회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from Aptamer Science regarding the adjustment of the conversion price of its convertible bonds (CB) due to a bonus issue (free capital increase). This type of disclosure, which details changes to the capital structure and conversion terms of financial instruments, falls under the category of capital and financing updates.
2023-03-02 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.